Incidence of and risk factors for community acquired pneumonia in US HIV-infected children, 2000-2005

AIDS

Volumn 25, Issue 5, 2011, Pages 717-720

  Steenhoff, Andrew P ^a   Josephs, Joshua S ^b   Rutstein, Richard M ^a   Gebo, Kelly A ^b   Siberry, George K ^c   Gaur, Aditya H ^d   Warford, Robert ^e   Korthuis, P Todd ^f   Spector, Stephen A ^b,g   Shah, Samir S ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b Department of Medicine ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; UNITED STATES; VIRUS LOAD;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; PNEUMONIA; RISK FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 79952454054     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283440583     Document Type: Article

References (15)

1. Mofenson LM, Yogev R, Korelitz J, Bethel J, Krasinski K, Moye J Jr, et al. Characteristics of acute pneumonia in human immunodeficiency virus-infected children and association with long term mortality risk. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Pediatric Infect Dis J 1998; 17:872-880. (Pubitemid 28506407)
2. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatric Infect Dis J 2000; 19:1141-1147. (Pubitemid 32003356)
3. Jones N, Huebner R, Khoosal M, Crewe-Brown H, Klugman K. The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population. AIDS (London, England) 1998; 12:2177-2184. (Pubitemid 28495272)
4. Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, Seage GR. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. J Am Med Assoc 2006; 296:292-300. (Pubitemid 44079313)
5. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatric Infect Dis J 2002; 21:810-815.
6. Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J, Korgenski K, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005; 41:21-29. (Pubitemid 40863739)
7. Kaplan SL, Mason EO, Wald ER, Schutze GE, Bradley JS, Tan TQ, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004; 113:443-449. (Pubitemid 38280781)
8. Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatric Infect Dis J 2004; 23:485-489. (Pubitemid 38802290)
9. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-1746. (Pubitemid 36514704)
10. Schutze GE, Tucker NC, Mason EO Jr. Impact of the conjugate vaccine in Arkansas. Pediatric Infect Dis J 2004; 23:1125-1129.
11. Haddy RI, Perry K, Chacko CE, Helton WB, Bowling MG, Looney SW, Buck GE. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine. Pediatric Infect Dis J 2005; 24:320-323. (Pubitemid 40525339)
12. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369:1179-1186. (Pubitemid 46527876)
13. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease: United States, 1998-2003. Morb Mortal Wkly Rep 2005; 54:893-897.
14. Hughes WT, Dankner WM, Yogev R, Huang S, Paul ME, Flores MA, et al. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis 2005; 40:136-145. (Pubitemid 40053471)
15. Buskin SE, Newcomer LM, Koutsky LA, Hooton TM, Spach DH, Hopkins SG. Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:201-206. (Pubitemid 29063720)